• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is ERAMET (ENXTPA:ERA) Undervalued After Its Québec Lithium JV Move?

    Simply Wall St·07/13/2026 05:21:47
    语音播报

    Eramet (ENXTPA:ERA) is back in focus after signing a Letter of Intent with Harfang Exploration for a potential joint venture on the Serpent lithium focused project in Québec, marking a fresh North American critical minerals push.

    See our latest analysis for ERAMET.

    The LOI comes after a weaker run for ERAMET's share price, with the 30 day share price return down 20.04% and the year to date share price return down 28.41%. The 1 year total shareholder return is down 12.67%, pointing to fading momentum despite interest in battery minerals.

    If this critical minerals story has caught your attention, it could be worth scanning other lithium and rare earth focused opportunities through the 30 best rare earth metal stocks

    Eramet clearly has scale in manganese and nickel and is pushing harder into lithium. Yet the share price has retreated sharply over the past year, so does the current valuation still reflect that underlying business strength?

    Preferred Price-to-Sales of 0.5x: Is it justified?

    On the numbers provided, ERAMET screens as inexpensive, with a P/S of 0.5x sitting against its recent share price of €44.1 and a weaker longer term return profile.

    The P/S ratio compares the company’s market value to its revenue, so a lower figure can suggest the market is assigning a modest value to each euro of sales. For a diversified miner like ERAMET, with exposure to manganese, nickel, lithium and mineral sands across several regions, this ratio is a simple way to compare its pricing to other metals and mining stocks without relying on current earnings.

    Against peers, ERAMET’s 0.5x P/S is below the peer average of 0.9x and below the European Metals and Mining industry average of 1.1x. This indicates the market is pricing its revenue at a lower level than many competitors. It is also well below an estimated fair P/S of 2.3x. This points to a large gap between the current market multiple and a level that regression analysis suggests the stock could move toward if sentiment or fundamentals shift.

    Explore the SWS fair ratio for ERAMET

    Result: Price-to-sales of 0.5x (UNDERVALUED)

    However, ERAMET still faces risks, including its recent multi-year decline in shareholder returns and its current net loss, which could weigh on sentiment around any re-rating story.

    Find out about the key risks to this ERAMET narrative.

    Another view on ERAMET using the SWS DCF model

    The P/S discussion suggests ERAMET looks inexpensive, but the SWS DCF model goes further and indicates the stock at €44.1 is trading below an estimated future cash flow value of €83.52. On this view, ERAMET screens as undervalued. However, how much faith should you place in long range cash flow estimates?

    Look into how the SWS DCF model arrives at its fair value.

    ERA Discounted Cash Flow as at Jul 2026
    ERA Discounted Cash Flow as at Jul 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ERAMET for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 212 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    With Eramet looking inexpensive on several measures yet still carrying clear risks, it makes sense to review the full picture yourself and act promptly while sentiment remains mixed by checking the 4 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Eramet?

    If Eramet has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other ideas that could suit different goals and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.